AZD-3965

Research use only, not for human use.

AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1).

AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM. In vivo, AZD3965 is well tolerated and induces a dose and time dependent accumulation of lactate in the tumours, suppresses tumour growth and in the Raji model potentiates the effects of Rituxan, doxorubicin and bendamustine. The selective inhibition of lactate transport by the MCT1 inhibitor AZD3965 offers an novel mechanism for targeting the metabolic phenotype in tumours that preferentially express MCT1.

AZD3965; AZD-3965; AZD 3965

Tyrosine Kinase

TAM Receptor

MCT1

Cancer

——

1448671-31-5

515.51

C21H24F3N5O5S

98%

DMSO : ≥ 36 mg/mL. 69.83 mM

O=c1n(C(C)C)c2c(c(C(=O)N3C[C@@](CO3)(O)C)c(Cc3c(C(F)(F)F)[nH]nc3C)s2)c(=O)n1C

(S)-5-(4-hydroxy-4-methylisoxazolidine-2-carbonyl)-1-isopropyl-3-methyl-6-((3-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione

(-20℃)

With Ice Pack

≥ 2 years